Tesaro, Inc.

This phase 3 study tests whether adding two drugs (dostarlimab and niraparib) to standard chemotherapy helps people with advanced ovarian cancer live longer without their cancer growing. About 1,400 participants with stage III or IV ovarian cancer will receive either the new comb…

This study tests a new drug called TSR-022 in people with advanced solid tumors that have not responded to other treatments. The drug aims to help the immune system fight cancer by blocking a protein called TIM-3. The trial has two parts: first, finding a safe dose, and second, t…

This study tests a drug called niraparib as a long-term maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished initial chemotherapy and had a good response. The goal is to see if taking niraparib can delay the cancer from coming back. Ab…

This study is testing an experimental drug called dostarlimab (TSR-042) in people with advanced solid tumors who have run out of standard treatment options. The drug works by helping the immune system attack cancer cells. The study has two parts: first, finding the safest dose, a…

This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants will receive either dostarlimab plus chemo or a placebo plus che…